Healthleap lands $38M to flag at-risk hospital patients with AI

Healthleap has raised $38 million across a seed round and a Series A to scale its AI platform, which reads hospital patient charts overnight and surfaces inpatients who may be suffering from conditions clinicians have not yet caught.

The round combines an $8 million seed co-led by Sequoia Capital and First Round Capital with a $30 million Series A led by Hummingbird Ventures. The company is not disclosing its valuation.

Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, Healthleap originally offered a clinical nutrition tool Jemima had built for dietitians. It later pivoted to a more general-purpose screening platform. CEO Josiah Meyer said the company has grown from three hospital partners to more than 50 over the past year, including Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. Revenue has grown more than 10x in that window, he said, without providing absolute numbers.

The story matters because Healthleap is selling into one of the most expensive blind spots in U.S. healthcare: patients whose underlying conditions — malnutrition, delirium, aspiration risk — slip past rounds and surface only after discharge, in a readmission, or in a denied claim. The startup's bet is that large language models can mine the unstructured half of the medical record and surface those patients in time for a clinician to act.

What the product actually does

Each night, Healthleap's software ingests a hospital's electronic health record system. It pulls structured fields — labs, weights, vital signs, medications, diagnoses — and runs language models over the rest: clinician notes that mention poor appetite, recent weight loss, muscle wasting, or trouble swallowing. By morning, the system writes a risk score into the care team's existing workflow, alongside a dashboard of patient trends.

"A patient's chart holds two kinds of data," Meyer said. "Labs, weights, and vital signs sit in structured fields, but the most telling signs sit in clinicians' written notes: poor appetite, recent weight loss, muscle loss, trouble swallowing. Our developing approach is extracting affirmative or negated mentions of these clinical concepts in an easily extensible and scalable way."

The platform screens for malnutrition and delirium today. Programs to flag aspiration pneumonia, pressure ulcers, and readmission risk for congestive heart failure are undergoing further clinical validation. The company stresses that its software does not diagnose; it surfaces cases for human review.

Why malnutrition first

Malnutrition is a deliberate starting point. Research cited by Healthleap suggests 20% to 50% of hospital inpatients are malnourished at admission, with downstream consequences including longer stays, impaired wound healing, infections, and higher morbidity and mortality. Conditions like this are easy to miss on a busy ward, but they are also lucrative for hospitals that document and code them correctly.

That economics explains a key part of Healthleap's pitch. U.S. payers increasingly reimburse for documented malnutrition and similar comorbidities, which gives the company a measurable dollar figure to anchor its contracts to.

How the contracts work

Healthleap sells three-year deals priced on a hospital's licensed bed count. On top of that base sits an outcome-based component tied to the financial return a hospital's finance team validates and attributes to the software.

"We use the hard ROI that the hospital finance team validates and attributes to us as the measurable ROI," Meyer said. "Based on that, we contractually ensure that we deliver multiples of the contract price. To date, every customer has seen a 5x hard ROI or more, in some cases over 20x annual total ROI."

The flagship number so far comes from the Hospital of the University of Pennsylvania, a Penn Medicine facility. Healthleap's malnutrition program there generated $23.8 million in annualized financial impact:

• $6.3 million from additional reimbursement
• $17.5 million from shorter hospital stays

The company plans to spend the fresh capital on engineering, product, sales, and customer success as it adds more conditions and pushes beyond the inpatient setting. Meyer said the longer-term goal is to cover more than 40 major health conditions and to extend the platform into outpatient and home care.

The regulatory and competitive stakes

Healthleap is one of a growing cohort of startups trying to monetize large language models inside the hospital chart. That market sits at the intersection of two contested categories: ambient documentation tools competing for the same physician attention, and clinical decision support software increasingly in the FDA's sights as the agency sharpens oversight of AI-enabled medical devices.

Healthleap's positioning — read the notes, surface the patient, hand the case back to a clinician — keeps it on the safer side of the diagnostic line. That distinction matters as hospitals weigh vendor risk and as regulators sharpen scrutiny of tools that move toward autonomous triage or diagnosis.

What to watch next

Three things will determine whether Healthleap graduates from a malnutrition story into a broader clinical-AI platform:

• Clinical validation of the next conditions. Aspiration pneumonia, pressure ulcers, and CHF readmission risk are still in validation. The credibility of the 5x ROI claim depends on whether the same playbook translates to other conditions and to other hospital systems beyond Penn Medicine.
• Reimbursement durability. A meaningful chunk of the Penn Medicine impact ($6.3 million) came from additional reimbursement tied to better documentation. If payers tighten coding audits or revisit malnutrition reimbursement, the ROI math changes.
• Expansion into outpatient and home care. Meyer has named both as priorities. Inpatient screening is a defined workflow. Outpatient and home are not, and the chart structures, EHR vendors, and reimbursement paths all differ.

Healthleap enters its next phase with three years of runway and a roster of marquee U.S. health systems on its logo slide. The question is whether a model trained to spot a missed case of malnutrition in a hospital note can do the same thing for the dozens of other conditions that quietly shape a patient's bill — and their recovery.